Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
A phase 3 trial of Olaparib, Abiraterone acetate in prostate cancer, run by AstraZeneca, active and no longer recruiting.
Overview
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) is a phase 3 interventional study registered as NCT05171816 by AstraZeneca, with 110 participants enrolled, started 2021-06-24 and due to reach its primary completion in 2024-01-22. Interventions recorded: olaparib, abiraterone acetate. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPROpel
Shares Abiraterone acetate, Olaparib, Prostate cancer.
- TrialFPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Shares Olaparib, AstraZeneca, Prostate cancer.
- TrialRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Shares Olaparib, AstraZeneca.
- TrialD9319C00001- 1L OC Mono Global RCT
Shares Olaparib, AstraZeneca.
- TrialEfficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
Shares Olaparib, AstraZeneca.
- TrialOlaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Shares Olaparib, AstraZeneca.
- TrialStudy of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
Shares Olaparib, AstraZeneca.
- TrialA Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
Shares Olaparib, AstraZeneca.